Navamedic ASA (N1A.F)
| Previous Close | 2.8500 |
| Open | 2.8900 |
| Bid | 2.8500 x 0 |
| Ask | 2.9600 x 0 |
| Day's Range | 2.8500 - 2.8900 |
| 52 Week Range | 2.6800 - 3.7100 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | 49.695M |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | 28.50 |
| EPS (TTM) | 0.1000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireNavamedic welcomes new shareholders
Navamedic (OSE: NAVA) is pleased to welcome new shareholders and delighted to see existing shareholders acquire a bigger stake following Ingerø Reiten Investment Company's (IRIC) sale of its entire 17.1 percent interest in the company.
PR NewswireNavamedic ASA: Notification of major shareholding and mandatory notification of trade
Ingerø Reiten Investment Company AS ("IRIC") has today sold all of its shares in the Nordic pharmaceutical company Navamedic ASA. The shares were sold for 32 kroner per share, for total gross proceeds of approximately NOK 95 million, or about 2.7 times the amount invested. IRIC has been Navamedic's principal owner and strategic partner since 2019. IRIC will use part of the proceeds to strengthen its balance sheet by paying off debt.
PR NewswireNavamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives
Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark.
